Background {#Sec1}
==========

Increasing access to antiretroviral therapy (ART) for people living with HIV/AIDS has been identified as a key strategy to curb the HIV epidemic and avoid its cost in the future \[[@CR1]\]. In 2015, an estimated 15 million people living with HIV/AIDS (PLWHs) were receiving ART, a remarkable milestone in the fight against HIV/AIDS \[[@CR2]\]. However, in order to achieve the ambitious sustainable development goal of ending the HIV epidemic by 2030, greater efforts are required in expanding ART coverage and improving quality of services with innovative and effective service delivery models.

In a number of the low and middle income countries (LMICs) most affected by the epidemic, decentralization of HIV treatment and care, linked with task-shifting, has been implemented in response to the need for scaling up service provision \[[@CR3]\]. Evidence from existing systematic reviews suggests that relocation of ART services closer to patients' homes through decentralized care can improve patient access and adherence to HIV treatment with non-inferior quality of care as compared to centralized, hospital-based care \[[@CR4]--[@CR6]\].

Current WHO guidelines on the use of ARV drugs for HIV treatment and prevention strongly recommend virological monitoring as the strategy of choice for monitoring responses to ART \[[@CR7]\]. Immunological monitoring (CD4 testing) is being scaled back for assessment of treatment responses where VL testing is available, but will still be required for the foreseeable future in many settings to determine the level of HIV-induced immune deficiency, including the need for screening and prophylaxis for serious co-infections, and to prioritize initiation of HIV treatment. Clinical monitoring is essential for all patients who are receiving ART to monitor patient responses to treatment and diagnose potential treatment failure \[[@CR8]\]. In addition, monitoring of ARV drug toxicity is recommended, as delaying drug substitutions when there are adverse drug effects may not only cause harm but also result in non-adherence leading to drug resistance and treatment failure. The latter will compromise the effectiveness of available ART regimens, increase spread of drug-resistant HIV, increase HIV incidence, morbidity and mortality and negatively impact the long-term sustainability and efficacy of ART programs in LMICs.

Given the current limited health system capacity in many LMICs, meeting WHO's recommendations regarding regular monitoring of patients' responses to treatment, including monitoring of drug toxicity, may pose major challenges to the health system with possible negative impacts on quality and sustainability of HIV services in the future \[[@CR9], [@CR10]\]. This vulnerable situation is particularly likely while rapid scale up of decentralized provision of ART is being prioritized.

This systematic review assessed the feasibility of ART treatment monitoring in settings of decentralized HIV treatment and care in LMICs.

Methods {#Sec2}
=======

Literature search strategy {#Sec3}
--------------------------

The preferred reporting item for systematic reviews and meta-analysis (PRISMA statement) \[[@CR11]\] was used to guide the conduct of this review. A literature search strategy was developed to identify relevant studies that involve decentralization of HIV treatment and care in low and middle income countries, published in English between Jan 2006 and Dec 2015. Key search terms include MeSH and free text terms relevant to HIV infection, HIV treatment and care, health service delivery models and service accessibility such as: "HIV", "HIV infection", "Antiretroviral therapy", "ART", "HAART", "delivery of health care" "primary health care", "community health services", "home-based\*", "decentral\*", "task-shift\*". Search terms also included those that refer to treatment monitoring including "treatment outcomes", "adverse effect" and "toxicity". The search strategy was first conducted in Medline (see Additional file [1](#MOESM1){ref-type="media"}: Annex S1), then adapted to run across CENTRAL, CINAHL, EMBASE, Scopus and Web of science. Conference abstracts were also searched from International AIDS Society and CROI conference websites. Grey literature resources and reference lists of existing systematic reviews were searched to identify relevant studies. For the purpose of this review, "feasibility" is defined as capacity of health system to provide and patient's accessibility to ART monitoring services following WHO's recommendations \[[@CR7]\].

Study selection {#Sec4}
---------------

Studies met inclusion criteria for this review if they: (i) involved HIV infected patients requiring ART and treatment follow-up, and/or healthcare workers involved in providing ART services; (ii) involved a decentralized model of HIV treatment and care which was defined as ART initiation and/or ART monitoring services provided at non-hospital settings: primary health facility or community level (through home-based delivery or community outreach including mobile health services); and (iii) reported one or more of the primary outcomes of interest as defined below.Proportion of patients receiving (with data documented) CD4 count, clinical HIV staging, and/or HIV viral load monitoring at treatment follow-up at regular intervals (6 or 12 months);Proportion of patients receiving ARV drug toxicity monitoring (clinical and/or biomedical) at treatment follow-up at regular intervals; and/orReported enablers, barriers and other implementing issues related to monitoring of ART services, including any of the following (a) human resources (availability and quality of clinical staff; staff competency training); (b) availability of, and access to, clinical, biochemical monitoring tools for monitoring treatment response, diagnosing ARV drug toxicity, and/or treatment failure; (c) supply chain management: reagents, equipment maintenance, etc. under decentralized HIV care; (d) patient and provider's attitude towards decentralization of HIV treatment and care.

Secondary outcomes included: (1) Proportion of patients with reported treatment failure, and (2) Proportion of patients who switched to a second line ARV drug.

In order to be eligible for inclusion, studies must have been conducted in LMICs and have reported at least one primary outcome or provided data which allowed for calculation of treatment monitoring uptake.

Data extraction and data synthesis {#Sec5}
----------------------------------

Data were extracted electronically using a pre-constructed, standardized data extraction form. Double data extraction with 20% duplication was performed by two independent reviewers. Extracted information included: study details (author/year, objective, design, number of patient enrolled), study population criteria, mode of ART services and outcome of interest. Data on outcomes of interest were grouped, presented and compared by models of service delivery (decentralized vs centralized), time point of treatment follow-up, and study design/study setting context. Quantitative data were presented and analyzed descriptively and data across studies were pooled, provided study interventions and populations were sufficiently similar. Qualitative data were thematically categorized using main themes relevant to the research questions, which emerged from data extracted.

Results {#Sec6}
=======

Study characteristics {#Sec7}
---------------------

The search strategy identified 5363 titles after duplicates were removed. Screening of titles plus abstracts with exclusion of clearly irrelevant studies resulted in 58 eligible studies for full text review, of which 20 studies (19 articles and one abstract \[[@CR12]\]) met all of the inclusion criteria, and were included in the review (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Selection process of included studies

All but one of these 20 studies were conducted in sub-Saharan Africa (SSA): 10 studies were from various urban, peri-urban and rural settings in South Africa (SA), one study was from rural and urban Ethiopia, one from rural Lesotho, one from rural and urban Kenya, two from rural Rwanda, one from urban Mozambique, one from rural Zimbabwe, two from rural Swaziland, and one from Asia (Thailand). Only two studies were specifically designed to assess the coverage of HIV treatment monitoring services in a decentralized setting; other studies evaluated and reported treatment outcomes. Only one study reported the proportion of patients who developed drug toxicity and two studies provided qualitative data (Table [1](#Tab1){ref-type="table"}).Table 1Characteristic of included studiesFirst author, yearStudy designStudy participantStudy location/countryStudy objectiveModel of ART servicesAdditional resources providedStudy duration/periodNumber of patient enrolledOutcomes of interestPrimarySecondaryAssefa, 2011 \[[@CR30]\]Mix method: retrospective cohort and qualitative studyHIV patient started ART at health facilities providing ART services55 health facilities 25 health centers and 30 hospitals representing different regions of EthiopiaTo evaluate outcomes of ART services at health centers vs hospitalART services led by health officer, nurses and CHWs at health centerCommunity health workers: adherence counseling, defaulter tracking referral and linkage between facilitiesSep 2006--Mar 20096206 at health centers; 31,929 at hospitalsProportion of patient with CD4 count documented\
Stakeholder's perspectives on new decentralized model of careBedelu, 2007 \[[@CR17]\]Retrospective cohortAdult HIV patientPrimary care clinics and hospitals/Lusikisiki, South Africa (SA)To assess the effect of decentralization and task-shifting on treatment outcomesART service led by nurses at health clinicMSF supported through mobile team visit, training/mentoring of nurse; engage community through support groupsApr 2004--Apr 20061025 (595 at clinic; 430 at hospital)Proportion of patient with CD4 count and VR data documentedBoulle, 2010 \[[@CR19]\]Retrospective cohortAdult treatment naïve HIV patient ≥14 years oldHIV treatment program at three public primary care clinics (PHC) Khayelitsha, SATo describe outcomes of ART program for adult up to 5 yearsNurse based care with stable patients seen by a nurse 2--3 monthlyProgram established/supported by MSF2001--20077323Proportion of patient with CD4 count and viral load data availableProportion of patient reported treatment failure; % patient switch to 2nd line ARTBrennan, 2011 \[[@CR16]\]Retrospective cohortART naive patient \>18 years oldUrban HIV clinic and local PHC in Johannesburg SATo compare one year outcomes between patient down-referred and maintained at central clinicART initiated at hospital and then follow-up at PHC by nurseNurse received down-reference training; supervise by doctor, plus advice by electronic treatment algorithmApr 2004--Sep 20082772Proportion of patient with 12 month CD4 and VL availableFatti, 2010 \[[@CR41]\]Retrospective cohortART naïve adult patient \>16 years59 public facilities: 47 PHCs, nine district and three regional hospitals in four provinces of SATo compare treatment outcomes at different levels of health system (primary health care, district and regional hospital)ART services led by doctor at different levelsCommunity-based adherence counselor; all sites supported by NGO (absolute return to kids) with free services to HIV patientsDec 2004--Dec 200729,203Proportion of patient with viral load resultsFairall, 2012 \[[@CR13]\]Randomized control trialAdult patient who had received ART for at least 6 months and were on ART at time of enrollment31 clinics (16 intervention and 15 control) in free state of SATo assess effects of task-shifting program on treatment outcomesART service led by nurse at primary care clinics (intervention) vs doctor at hospital OPC (control)Outreach training for nurses with doctor supportJan 2008--Jun 20103029 (intervention) 3202 (control)Proportion of patient with VR data availableHumphreys, 2010 \[[@CR27]\]Prospective cohortAdult patient on ART at least 4 weeks CD4 \>100Primary care clinics and district hospital in rural SwazilandTo assess effect of nurse led primary care based ART programART service led by nurse at primary care clinics vs doctor at hospitalTraining for primary care nurses by hospital followed by monthly outreach support visitsJan--Nov 2007474Patient experience with primary based ART programHansudewe-chakul, 2012 \[[@CR15]\]Retrospective cohortHIV infected childrenTertiary hospital and community hospital in rural ThailandTo assess effects of decentralization of pediatric HIV care modelART initiated at tertiary hospital, monitored at community hospitalTraining and mentoring for CH staffs; trained PLHIV: adherence, psychological supportFeb 2002--Mar 2008410Proportion of patient with VL data recordedJanssen, 2010 \[[@CR21]\]Prospective cohortHIV patient \<15 years on ARTPrimary care clinics, KwaZulu-Natal, SATo assess clinical outcomes of children in a decentralized modelNurse/counselor led ART programHome-based care program with nurse/community volunteer providing first aids, nutrition, adherence support at homeJun 2004--Jun 2008477Proportion of patients receiving CD4 and VL monitoringJobanputra, 2014 \[[@CR26]\]Retrospective cohortHIV patient on ARTPrimary health care clinics in rural poor Shiselweni region of SwazilandTo assess program quality, cost and outcomes of routine VL monitoringNurse led ART programMSF support (laboratory equipment, reagent, training of staff)Oct 2012--Mar 20135563Proportion of patients receiving routine VL monitoringReported treatment failure rate; % patient switch to 2nd line ARTLabhardt, 2012 \[[@CR29]\]Retrospective cohortHIV patient \>16 years old on ART with at least three drugsTwo hospital and 12 health centers of Botha-Bothe ad Thaba-Tseka districts of LesothoTo assess the effectiveness of decentralized ART programNurse led ART programART program supported by a Swiss NGO through the SolidarMed ART projectJan 2008--Apr 20113747Availability of treatment monitoring tools at decentralized settingsMutevedzi, 2010 \[[@CR20]\]Retrospective cohortAdult patient \>16 years old16 primary care clinic in rural SATo describe and assess scale-up of decentralized HIV treatment programART initiated by doctor and monitored by nurseSupport for program provided by PEPFAROct 2004--Sep 20083010Proportion of patient with VL data recordedRich, 2012 \[[@CR22]\]Retrospective cohortHIV patient on ARTART clinics at health centers in rural RwandaTo assess clinical outcomes of HIV treatment programCommunity-based ART program with directly observed ART and psychosocial supported provided by CHWsOngoing HIV education, nutritional assistance, travel allowance for clinic visits, diagnosis and treatment of TB; additional doctor/provider supportJun 2005--Apr 20061041Proportion of patient with CD4 and VL monitoring data availableProportion of patient change treatment regimen due to toxicity; % patient switch to 2nd line ARTSelke, 2010 \[[@CR14]\]Randomized control trialHIV patient, 18 years stable on ART at least 3 monthsHIV clinic in rural health center of KenyaTo assess impact of task shiftingNurse led ART service with home based visit by community care coordinator (CCCs) vs standard of care (no CCCs)Electronic device support tool (PDA) for patient monitoring; program supported by USAIDMar 2006--Apr 2008208 (96 intervention; 112 control)Proportion of patient monitored with clinical, immunological, virological dataShumbusho, 2009 \[[@CR24]\]Retrospective cohortHIV treatment-naïve adult patientsThree rural primary health centers in RwandaTo evaluate results of pilot task-shifting model for ART service provisionNurse centered ART services (initiation management and referral of complex casesAdditional personnel provided for intervention (specific number not reported)Sep 2005--Mar 20081076 (641 pre-ART and 435 on ART)Proportion of patient with CD4 count documentedProportion of patient change treatment regimen due to toxicity; % patient switch to 2nd line ARTSanne, 2010 \[[@CR25]\]Randomized control trialAdult HIV-1patient (\>16 year old, CD4 \<350 or previous AIDS defining illness; not pregnant)Two primary health care sites in Cape town and Johannesbur, SATo compare outcomes of nurse vs doctor management of ARTART services led by nurses (vs doctor led): full decentralizationNot reportedFeb 2005--Jan 2009812Proportion of patient reported drug toxicityUzodike, 2015 \[[@CR18]\]Cross-sectionalAdult HIV patient on ARTPrimary healthcare (PHC) clinics in Kwazulu-Natal, SATo assess monitoring and referral of patient on ART managed at PHC clinicsART services led by nursesNot reportedJun 2011--Jun 2012488Proportion of patients with CD4 VL monitoring data available% patient reported virological failureVogt, 2015 \[[@CR23]\]Retrospective cohortHIV patient \>18 years old initiated on ART at district hospital and rural health clinics (RHCs)Beitbridge district hospital and six RHCs in Matabeleland South province, ZimbabweTo compare coverage of CD4 testing between rural and urban HIV patient during 1st year of treatmentHIV care services provided by nurses at RHCs through weekly outreach visitsServices provision supported by MSF (MSF nurse and phlebotomy equipment)Jan 2011--Dec 20122145Proportion of patients receiving CD4 testingWalter, 2014 \[[@CR12]\]Before--after (decentralization) comparisonHIV adult patients initiated on ART at primary health centersTo compare treatment outcomes before and after decentralizationART service led by nurses at primary health care centerNot reported2003--2006 (before) 2009--2011 (after)3936 (before); 13,505 (after)Proportion of patient with CD4 count documentedGeorgeu, 2012 \[[@CR28]\]QualitativeHIV patient, service providers (physician, nurse)Primary health care clinics in free state of SATo explore experience, perceptions of various stakeholders on implementation process of decentralization of ART servicesART service led by nursesNot reportedOct 2007--Jun 200816 FGDs, 26 in-depth and key informant interviewImplementing issues related to decentralization\
Stakeholder's perspective on decentralization

HIV viral load (VL) monitoring {#Sec8}
------------------------------

Twelve studies (Table [2](#Tab2){ref-type="table"}) provided data regarding the proportion of patients who received regular VL monitoring, among which 11 studies reported the proportion of patients receiving VL monitoring at 12 months follow-up, with a median service uptake of 86%. The highest coverage of virological monitoring services was reported from two randomized control trials (RCT) conducted in SA \[[@CR13]\] and Kenya \[[@CR14]\] with 92% (2582/2823) and 99% (86/87) uptake; both studies were conducted by dedicated research staff who were not part of the routine clinical service. The lowest reported proportion of patients with VL monitoring data came from a retrospective cohort study conducted between 2002 and 2008 in rural Thailand \[[@CR15]\] with only 14.3% (22/154) of patients having VL data available at baseline and at least one treatment follow-up 12--48 months after treatment initiation. The authors reported that routine VL testing was not available, baseline VL data were available only for a subset of the study participants and VL was determined at 12 months intervals during the 48 months of study.Table 2Uptake of regular monitoring for patients on ART at different time points of treatment follow-upFirst author, yearFollow-upsNumber of patient retained in careProportion of patient monitored for treatment response n (%) by \# monitoring approachesLaboratory testing servicesTesting siteNotesVirologicalImmunologicalClinical^a^Assefa, 2011 \[[@CR30]\]6 monthsHealth center: 5072/6197\
Hospital: 24,821/31,269Not report (NR)54%NRNot statedNot statedNumber of patients received immunological monitoring with CD4 count documented was not reported. Data (proportion of patient monitored) was not reported separately for each level of care12 monthsHealth center: 3042/4022\
Hospital: 17,037/23,039NR51%24 monthsHealth center 650/856\
Hospital : 4419/6595NR51%Bedelu, 2007 \[[@CR17]\]12 monthsHealth clinic: 482/595\
Hospital: 289/430Health clinic: 296/482 (61.4%)\
Hospital: 41/289 (14.2%)Health clinic: 348/482 (72.2%)\
Hospital: 81/289 (28%)NRNot statedNot statedBoulle, 2010 \[[@CR19]\]1 year45123932/4512 (87%)3823/4512 (85%)NRCD4 and VL provided 6-monthly after staring ARTNot statedVL: NucliScens EasyQHIV-1 assay\
CD4: single-platform panleucogating method\
Type of blood used not reported2 years25612198/2561 (86%)2108/2561 (82%)3 years1235983/1235 (79.6%)931/1235 (75.4%)4 years458351/458 (76.6%)341/458 (74.5%)5 years191148/191 (77.5%)127/191 (66.5%)Brennan, 2011 \[[@CR16]\]12 monthsHospital : 1958/2079\
Primary health care: 681/693Hospital: 1774/1958 (90.6%)\
PHC 676/681 (99.2%)PHC: 95%\
Hospital: 81%Clinical monitor performed every 2 months by nurse at PHC; 6 monthly by doctor at hospitalCD4 and VL test measured every 6 monthNot statedInconsistency in data on % patients with CD4 and VL data available between text and table. Number of patients with 12 months CD4 count available not reportedFatti, 2010 \[[@CR41]\]12 months11,9606725 (56.2%)NRPatients attend monthly clinical checksCD4 count and VL monitored 6 monthly for patient on treatment by SA NHL servicesOff-site except for large hospitalData (n/N) on proportion of patient received and had VL available was reported for all level of care24 months40292525 (62.6%)36 months545342 (62.8%)Fairall, 2012 \[[@CR13]\]12 monthsPrimary care: 2823/3029\
Hospital: 2981/3202Primary care: 2582/2823 (91.5%)\
Hospital: 2656/2981 (89.1%)NRNRNot statedNot statedHansudewe-chakul, 2012 \[[@CR15]\]12, 24, 36, 48 months (VL data available at baseline and at least 1 follow-up)Community hospital: 154\
Tertiary hospital : 133CH: 22/154 (14.3%)\
TH: 38/133 (28.6%)NRClinical monitoring using CDC classification;CD4% assessed 6 monthly, routine VL testing not available. VL measured at 12 month intervals for 48 monthsNot statedNo time point specific provided for % patient with VL data available. Scheduled clinic visit 6 monthly at tertiary hospitalJanssen, 2010 \[[@CR21]\]6--12 months447193/447 (43.2%)CD4%: 310/447 (69.3%); CD4: 315/447 (70.5%)NRLaboratory tests (CD4, VL, Hemoglobin/albumin) repeated 6 monthlyVL testing at referral hospital (75 km away); other tests at local hospitalJobanputra, 2014 \[[@CR26]\]12 months55634767/5563 (86%)NRNRVL measured annually using a Generic HIV VL platform (Biocentric)VL testing at regional virology laboratoryMutevedzi, 2010 \[[@CR20]\]12 months2527/3010758/2527 (30%)NRNRCD4 count and VL measured every 6 monthsVL testing at provincial labVL measured by Nucli-Sens Easy HIV-1 assay). Type of blood used not reportRich, 2012 \[[@CR22]\]24 months926275/926 (29.7%)710/926 (76.7%)NRCD4 count measured 6 monthly using BD fluorescence-activated cell sorting count systemNot statedSelke, 2010 \[[@CR14]\]12 monthsIntervention: 87\
Control: 102Intervention: 86/87 (99%)\
Control: 96/102 (94.1%)Intervention: 87/87 (100%)\
Control: 96/102 (94.1%)Intervention: 74/87 (85%)\
Control: 87/102 (85.3%)VL and CD4 count obtained at initial and close out research visit. Additional CD4 count at 6 monthsNot statedShumbusho, 2009 \[[@CR24]\]6 months217NR193/217 (88.9%)83.4%: side effect screening at all visits (frequency not reported)CD4 count measured every 6 month using BD FACS CountDistrict hospital laboratory12 months123NR104/123 (84.5%)18 months43NR31/43 (72.1%)24 months1010/10 (100%)Uzodike, 2015 \[[@CR18]\]Jun 2011488407/488 (83.4%)461/488 (94.5%)412/488 (84.4%)CD4 and VL monitored 6 monthlyNot statedClinical monitoring carried out monthly by nursesDec 2011466/488 (95.5%)464/488 (95.1%)NRJun 2012444/488 (91.0%)430/488 (88.1%)381/488 (78%)Vogt, 2015 \[[@CR23]\]6 months1250NR194/1250 (15.5%)1250/2145 (58%)Whole blood collected in EDTA tube for testing by BD Fascount and Partect CyflowDistrict hospital laboratoryData is presented for both hospital and RHCs12 months1199NR74/1199 (6.2%)1199/2145 (56%)Walter, 2014 \[[@CR12]\]6 months11,243NR5859 (52%)NRNot statedNot stated12 months86445160 (60%)18 months64674110 (64%)24 months44853201 (71%)^a^Clinical monitoring using WHO clinical staging except mentioned otherwise

In four studies that reported the proportion of patients who received VL monitoring in both centralized and decentralized models of care, two studies reported a higher proportion of monitoring of patients attending centralized care (vs decentralized care): 99% (1774/1958) versus 91% (676/681) \[[@CR16]\] and 29% (38/133) versus 14% (22/154) \[[@CR15]\], while another two studies reported a similar or higher proportion of patients with access to VL monitoring with decentralized care (vs centralized care): 92% versus 90% \[[@CR13]\] and 61% (296/482) versus 14% (41/289) \[[@CR17]\]. In the two latter studies, both conducted in SA, the difference in service coverage between models of care was not discussed; however, one study \[[@CR13]\] reported results of a 30 month randomized trial aimed to assess the effects of an outreach training program provided to nurses for ART initiation and prescribing at primary care clinics while the other \[[@CR17]\] reported outcomes of a community-based, decentralized HIV services delivery program supported by Medecins Sans Frontieres (MSF).

Overall, studies conducted in urban settings reported a higher uptake of VL monitoring services: three studies conducted in urban HIV clinic settings in SA \[[@CR16], [@CR18], [@CR19]\] reported more than 80% of patients had VL data available after 6--24 months on treatment while three other studies in rural settings (two in South Africa \[[@CR20], [@CR21]\] and one in Rwanda \[[@CR22]\]) reported 30--43% of patients had access to this service at 12 months follow-up although almost all (five of six) studies stated that VL (and CD4) was planned to be measured 6 monthly for all patients on ART. The ability of nursing staff to establish virological failure for timely referral and regimen switch was a concern as only 59% of patients who demonstrated persistently elevated VL in two consecutive VL monitoring tests were referred for further treatment intervention \[[@CR18]\]. None of the included studies reported on-site VL or CD4 testing.

Among 12 studies that included data regarding virological assessment, only three studies reported the platform used for viral load testing (two studies with Nucli-Scens EasyQ HIV-1 and one study with a generic HIV VL platform-Biocentric) and none of these three studies discussed the blood sample used for VL testing (plasma or dried blood spot). None of the other nine studies reported how and where virological and/or immunological monitoring for patients on treatment was conducted.

Clinical and immunological monitoring {#Sec9}
-------------------------------------

The majority (15 of 20) of included studies reported the use of WHO clinical staging to assess and monitor patients' responses to treatment (Table [2](#Tab2){ref-type="table"}). Only three studies specifically provided data regarding the proportion of patients who received clinical monitoring through decentralized HIV treatment programs. The other 12 studies did not provide sufficient data for calculation of the coverage of clinical monitoring at decentralized settings.

One study \[[@CR18]\] conducted in urban SA assessed the adherence of nursing staff at a primary health care clinic to national guidelines regarding monitoring and follow-up of HIV patients on ART. In this retrospective, cross-sectional study the authors randomly selected and assessed medical records of 488 patients attending the clinic from June 2011 to June 2012 and reported 84% (412/488) and 78% (381/488) patients with clinical monitoring data available by June 2011 and June 2012 respectively.

Another study \[[@CR14]\] aimed to evaluate clinical outcomes of patients enrolled in a community-based HIV care program delivered by PLWHs (intervention group) as compared to patients receiving standard, clinic-based care (control group). The reported proportions of patients monitored clinically at 12 months follow-up were identical for both groups, 85% (74/87) for the control group and 85.3% (87/102) for the intervention group. One study \[[@CR23]\] reported a lower level of clinical monitoring coverage with 1250 (58%) and 1199 (56%) out of 2145 patients initiated on ART receiving clinical assessments at 6 and 12 months follow-up, respectively.

Among 11 studies with patient follow-up periods from 6 to 24 months, the reported proportion of patients with a CD4 count measurement with data recorded at 6--12 month intervals ranged from 6 to 100%. One study \[[@CR19]\] with follow-up data of up to five years reported that 67% (127/191) to 85% (3823/4512) of patients had their CD4 count measured, and 78% (148/191) to 87% (3932/4512) of patients having their VL measured, at 12 month intervals. Data from this study showed that the proportion of patients receiving immunological and virological monitoring decreased over time, although the total number of patients in care also reduced by 96% after 5 years on treatment (from 4512 after 12 months to 191 after 5 years follow-up).

Two studies provided data that compared coverage of immunological monitoring between decentralized and centralized HIV care sites and both studies reported a higher uptake of services in the decentralized model. One study \[[@CR17]\] reported 72% (348/482) of patients attending rural primary health care clinics versus 28% (81/289) attending a hospital had their CD4 count determined after 12 months of treatment. The authors reported that ART services provided at primary clinics were supported by Médecins Sans Frontières (MSF) with involvement of peer support groups to track defaulters, provide adherence support, advocate for better drug supply and monitoring of HIV program whereas no such supports were provided to patients receiving care at hospital. The second study \[[@CR16]\] reported 95% of down-referred (decentralized) patients (n = 693) versus 81% of centralized patients (n = 2079) had a CD4 count (and VL) available at 12 months but the information on treatment monitoring procedure (platform used for VL testing, type of blood sample used and place where VL testing performed) was not presented.

One study \[[@CR23]\] aimed to assess the coverage of immunological monitoring between HIV patients living in a semi-urban district in Zimbabwe and reported only 21 and 8% of urban (n = 1545), and 2 and 1% of rural patients (n = 600) had received CD4 testing at 6 and 12 months follow-up, respectively. The authors reported that CD4 testing at rural health centers was usually restricted to the day of outreach visits when outreach staff collected blood samples in Ethylenediaminetetraacetic Acid (EDTA) tubes and brought the blood back to the district hospital for testing within 24 h. Limited capacity for specimen transportation within local health systems was noted as the main reason for the differences in access to CD4 testing between rural and urban patients.

Toxicity monitoring {#Sec10}
-------------------

No study reported the proportion of patients receiving laboratory monitoring for ARV drug toxicity at scheduled monitoring visits in program settings. The proportion of patients who changed their initial regimen (drug substitution, not considered as switching to second line ART) due to drug toxicity was reported as ranging from 5% (161/3029) \[[@CR13]\] to 29% (304/1040) \[[@CR22]\]. One retrospective cohort study \[[@CR24]\] reported 83.4% of all patients were screened for side-effects at all visits but the frequency of visits was not stated. A randomized controlled trial \[[@CR25]\] reported 17% (68/404) and 16% (66/408) toxicity failure in patient groups managed by a nurse and by a doctor at primary care settings, respectively.

Secondary outcomes {#Sec11}
------------------

Three studies reported the proportion of patients with virological failure and four studies reported the proportion of patients who switched from 1st to 2nd line ART. The reported proportion of patients with treatment failure ranged from 14% (n = 4512) \[[@CR19]\] to 49% (n = 488) \[[@CR18]\] and the proportion of patients starting 2nd line treatment was from 0.5% (n = 1040) \[[@CR22]\] during 24 months follow-up to 12.2% (n = 4512) \[[@CR19]\] at 60 months on treatment. One study assessed the outcomes of routine VL monitoring of ART programs through a decentralized network of 22 primary care clinics and three reference facilities in Zimbabwe. These investigators reported 17% (551/3242) of VL tests had detectable HIV (\>1000 copies/µL) and among 288 patients with an initial detectable VL result, 78 patients (27%) did not receive adherence counseling, 86 (30%) patients had no follow-up VL, and 15 patients (5.2%) patients were switched to 2nd line treatment, among whom four patients were switched based on a single detectable VL result \[[@CR26]\].

Factors that influence the implementation and feasibility of decentralization {#Sec12}
-----------------------------------------------------------------------------

Data from included studies suggest that patients were supportive of decentralization of HIV treatment and care as it could help to improve their access to care (Table [3](#Tab3){ref-type="table"}). One study \[[@CR27]\] reported 96% (29/31) of patients interviewed were 'very satisfied' or 'satisfied' with HIV treatment services provided by nurses, and the main reasons for this included reduced cost, receiving services near home and shorter queue, and being treated better by staff. Health professionals also reported positive responses: nurses were comfortable, motivated, enthusiastic about the opportunity to be directly involved in providing life-saving treatment; physicians supported decentralization and nurse-led ART initiation as it could help increase ART coverage, but expressed uncertainty about the ability of nurses to manage and refer complicated cases \[[@CR28]\].Table 3Influencing factors for monitoring of ART services in decentralized settingsFirst author, yearReported implementing issues/barriers for ART services under decentralized care from system perspectiveAcceptability and reported quality of decentralized care from service provider and patient perspectivesAssefa, 2012 \[[@CR30]\]Policy: lack of regulation framework enabling nurse to perform tasks such as ARV prescription, monitoring of patients on ART\
Finance: high cost associated with training and monitoring quality of services\
Human resource: additional workload for nurse without increased remuneration/compensation; Community health workers were not permanent employee/formal health systemPatient's perspective: Nurse led ART services was well accepted, help to reduce waiting time; provide appropriate counseling; combat stigma and discrimination in society and can help to provide opportunity for employmentGeorgeu, 2012 \[[@CR28]\]Workload, including paperwork increased significantly for nurses and other team members through broader human resource shortage and lack of capacity (e.g. data capturers performed basic nurse duties when nurse too busy, nurse dispensed when pharmacist not available)\
Increased number of patients on treatment further strained scare/inadequate human and physical resources of health system: insufficiently staff and resources; fragmented information, poor patient transport/referral system; unreliable drug supplies due to poor communication, transport between pharmacy/central dispensing unit and clinicsNurses were comfortable, motivated, enthusiastic about opportunity to be directly involve in providing life-saving ART treatment\
Physicians reported mix attitude: majority support decentralization and nurse initiated ART but significant minority reported uncertainty about the ability of nurses to manage and refer complicate cases\
Patients were supportive of decentralization as it improved access to care, reduced travel time/cost but some wanting ART to remain a separate services and expressed preference toward physician services because of higher clinical status and only doctor can medically certify social grant---key source of income for people living with HIV/AIDS in South AfricaHumphreys, 2010 \[[@CR27]\]Among patients interviewed in intervention group (received nurse led/primary care based ART services) 81% (25/31) were very satisfied 13% (4/31) were satisfied 3% (1/31) dissatisfied and 3% (1/31) very dissatisfied as compared to services at main hospital\
Reasons for satisfaction includes: reduced cost, services provided nearer to home, shorter queue and being treated better by staff. Reasons for dissatisfaction were lack of doctor and delay of service because team from hospital arrive lateLabhardt, 2012 \[[@CR29]\]CD4, VL and biochemistry were not available on site at decentralized settings\
Hemoglobin was available in 2/5 and 2/7 health centers of two studied districts

A number of system factors that could hinder the implementation and scale-up of decentralization in low-resource settings were identified and discussed. These factors include: (i) Limited resources available for treatment monitoring services (ii) Lack of a policy framework which allows non-physician staff (nurses) to initiate HIV treatment; (iii) increased workload (clinical and administrative) for nurses without commensurate remuneration; (iv) unreliable antiretroviral drug supplies due to poor communication, inadequate transport between pharmacy/central dispensing unit and clinics; and (v) high costs associated with health worker training and monitoring of service quality \[[@CR29], [@CR30]\].

Discussion {#Sec13}
==========

Why treatment monitoring is important to achieve the 90-90-90 goal {#Sec14}
------------------------------------------------------------------

Monitoring of patients on antiretroviral treatment (ART), especially in the context of rapid scale up of ART coverage in high HIV burden and low-resource settings through different models of services delivery including decentralization, is one of the most important elements to ensure effectiveness and sustainability of any HIV treatment and care program. The "90-90-90" goal aims at having 90% of HIV positive people knowing their infection status; 90% of those people receiving ART, and 90% of those on ART with virologic suppression, and is considered a universal target needed to effectively control and ultimately end the global HIV epidemic. There are two key milestones that need to be achieved to make the last "90" target a reality. First, the majority (\>90%) of patients on ART must have access to appropriate and timely ART monitoring: 12-monthly VL assessment or 6-monthly clinical assessment and CD4 count if VL is not available. Second, effective treatment and well-functioning patient support systems including adherence coaching must be in place to achieve a majority (\>90%) of patients on ART with sustained viral suppression.

VL monitoring {#Sec15}
-------------

WHO has recommended VL testing as the preferred method for monitoring the responses of patients on ART \[[@CR8]\] and it has been suggested that in order to achieve the "90-90-90" goal, viral load monitoring should and can become the standard of care in LMICs with high HIV prevalence \[[@CR31]\]. There is ample evidence showing that routine VL monitoring can provide an early and more accurate diagnosis of treatment failure when compared to clinical and immunological monitoring \[[@CR32], [@CR33]\], but evidence regarding the value of VL monitoring as compared to immunological monitoring in reducing mortality among patients on ART has been mixed \[[@CR34]--[@CR38]\]. Availability of, and access to, VL testing is still limited due to the requirements of expensive laboratory equipment, complex sample collection and processing, and the need for highly trained personnel \[[@CR39]\]. A recent WHO survey on availability and use of HIV diagnostics in LMICs found that the overall coverage of VL testing among patients on ART from 94 countries was 23% \[[@CR40]\]. In our review, a wide range of VL monitoring coverage was observed. Although we found a median VL monitoring coverage of 86% at 12 months follow-up, this level of coverage may not well reflect regular VL monitoring practice under decentralized HIV care models in LMICs. Among eight studies which reported VL monitoring rate of greater than 50% among patients on ART, five studies reported results of decentralized HIV programs supported by external donors such as MSF \[[@CR17], [@CR19], [@CR26]\], Absolute Return for Kids \[[@CR41]\], U.S. Agency for International Development (USAID) \[[@CR14]\], and two studies reported results of randomized trials in which VL testing was part of the funded studies in well-resourced settings \[[@CR13], [@CR14]\]. In addition, existing evidence suggests that the longer a patient is on ART the lower the rate of receiving regular VL test. Only three studies evaluated the long-term (more than 24 months) follow-up of VL coverage \[[@CR15], [@CR19], [@CR41]\]. Thus, further research is needed to examine patient retention and treatment monitoring practices with long-term follow-up, particularly in rural settings.

Clinical and immunological monitoring {#Sec16}
-------------------------------------

At decentralized primary care levels in LMICs, clinical and CD4 count monitoring remains a viable option to monitor treatment responses in settings where VL testing is not available. In our review, limited data were available to assess the feasibility and coverage of clinical and immunological monitoring in a decentralized model of HIV care, as only two studies provided data on the actual proportion of patients who received both clinical and CD4 monitoring. Of note, these are the two studies designed to assess treatment monitoring practice in two different settings, providing a contrasting picture of the coverage of treatment monitoring services. Differences in treatment monitoring coverage between these ART programs could be explained by study settings and service delivery models; one in an urban, well staffed HIV clinics with clinical staff on call and easy access to laboratory testing \[[@CR18]\] while the other was in rural areas with ART service provided by outreach teams and with long distances for sample delivery from clinics to a laboratory facility located at a district hospital \[[@CR23]\]. This finding highlights an important potential gap in existing knowledge. It has implications related to the implementation of treatment monitoring in future decentralized ART programs, particularly in rural, resource-constraint settings, as when only a minority of patients is engaged in an ART program where they receive regular monitoring, an increase in treatment failure and drug resistance can be foreseen.

Drug toxicity monitoring {#Sec17}
------------------------

Limited data were available to assess the feasibility of drug toxicity monitoring for patients on ART in decentralized settings. None of the included studies reported the proportion of patients on ART who received laboratory-based drug toxicity monitoring, but one RCT showed that the proportion of patients reporting toxic drug effects (defined as adverse events that required treatment interruption for \>42 days) during the study period was higher than the total virological failure rate among patients on ART \[[@CR25]\]. This finding is in line with results from other studies suggesting that drug toxicity is the most common reason for changing initial treatment regimen \[[@CR42], [@CR43]\]. The WHO guidelines emphasize that laboratory monitoring is not required for treatment initiation. However, there are major toxicities associated with ARV drugs that should be monitored in all patients on treatment. The basic monitoring for potential toxicity of drugs such as tenofovir, zidovudine and nevirapine require laboratory assessment of renal function, hemoglobin, and liver enzymes, respectively. Without the availability of, and access to, these basic tests, monitoring for ART toxicity cannot be performed, and could compromise the long-term effectiveness and sustainability of the ART program. Researches have showed that HIV patients on ART who have regimen substitution due to drug toxicity/drug related adverse reactions were at higher risk of loss to follow-up \[[@CR44], [@CR45]\] which may partly explain the significant reduction in number of patients in care after five years of follow-up reported from study included in this review \[[@CR19]\].

Barriers related to treatment monitoring and evaluation of treatment monitoring under decentralization {#Sec18}
------------------------------------------------------------------------------------------------------

### Technological constraints {#Sec19}

From a technology perspective, in the absence of point of care (POC) testing, access to laboratory monitoring for patients on ART under a decentralized model of care in low-resource settings will likely be limited. For VL monitoring; until the arrival of a true point of care VL test, the feasibility of VL monitoring for patients received ART at the primary clinic level will depend on system capacity to collect and process a blood sample, transport the sample to a central laboratory for testing and return the result in a timely manner. For immunological monitoring, there are CD4 POC technologies available that can be operated in decentralized settings and produce reliable results for treatment monitoring \[[@CR46]\]; their use has been shown to improve access to this alternative monitoring method and increases patient retention along the HIV treatment cascade compared to conventional laboratory testing \[[@CR47]\].

### Human resource constraints {#Sec20}

A lack of trained medical doctors for initiation and management of patients on ART has been identified as a major barrier for scaling up of ART programs \[[@CR48], [@CR49]\]. Task-shifting of HIV services from physician to non-physician carers has been introduced to overcome this challenge \[[@CR4], [@CR13]\]. From a treatment monitoring perspective, however, task-shifting does not come without challenges. Findings from our review suggest that increased clinical and administrative responsibilities associated with provision of nurse-led ART services could further burden the already-limited personnel at primary health care level. Primary health care staff reported their reluctance to put more PLWHA on treatment because of concern over their capacity to manage the burden of an increasing number of patients on ART. The quality of treatment monitoring could also be a concern as nursing staff were unable to identify and refer all cases of treatment failure at decentralized settings for regimen change, even with the availability of two consecutive VL monitoring results indicating virological failure. The lower than expected rate of patients initiated on second line ART may represent an appropriate strategy to optimize adherence before switching therapy but it may also indicate clinicians' lack of confidence regarding interpretation of VL results and second line treatment. The introduction of any new assay into a clinical setting requires education of the clinician in its interpretation; this is especially the case with a complicated tool such as a VL test. On the other hand, early switching to second line ART after a single detectable VL test without appropriately addressing non-adherence issues would potentially result in the unnecessary initiation of second line ART and, without addressing poor adherence would lead to suboptimal second-line outcomes \[[@CR50], [@CR51]\]. This is an important issue of concern particularly in settings where treatment options are limited and second and third-line regimens are costly.

### Recommendations {#Sec21}

In LMICs the challenge of limited coverage of, and access to, treatment monitoring services that is associated with decentralization of HIV treatment and care often lies within the health care system; therefore a comprehensive strategy to improve the practice of treatment monitoring should be considered from a health system strengthening perspective (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Health system challenges impacting access to ART monitoring (clinical/immunological, viral load and drug toxicity) based on data from studies included in the review

In terms of service delivery, treatment and treatment monitoring services should ideally be delivered close to where the patient lives, with appropriate diagnostic technology and human resource availability at the primary health care level. The development and implementation of POC technologies to provide immunological and virological monitoring are critically important to ensure appropriate treatment monitoring, particularly with further scale up of HIV treatment services in decentralized settings.

The impact of future studies towards improving the implementation of decentralized care would benefit from the inclusion of some standardized targets and outcomes in published reports. In the absence of clearly defined indicators and targets, the assessment and appraisal of coverage and quality of treatment monitoring services continues to be a challenge. Given the momentum in scaling up ART and towards achieving the 90-90-90 target, there is a need for standardized measures that can be used in many upcoming researches reporting global progress towards this ambitious goal. The development and adoption of a specific set of processes and target indicators regarding treatment monitoring could help to align the reporting system within different levels of health services provision, improve the timeliness of reporting results, and ensure that appropriate action is taken when results support particular interventions (e.g. adherence counseling).

Lastly, from governance and financing perspectives, it is obvious that if the ambitious "90-90-90" goal is to be achieved in 2020, the importance of treatment monitoring must be emphasized equally with the importance of treatment coverage. Substantial resources are required to ensure appropriate treatment monitoring for all people on ART. Critical to success is the assessment of system capacity, particularly human resources and health technology in delivering treatment monitoring. This must be conducted as an integrated component of the decision-making process in order to identify the optimal strategy to increase high quality coverage of HIV treatment and care services in any given specific setting. Expansion of ART coverage without considering system capacity for the provision of appropriate treatment monitoring to all patients will inevitably lead to more treatment failures and increased development of drug resistance, with resulting public health costs to address these problems. Therefore, the recommendation of WHO that lack of access to, or availability of, laboratory monitoring should not be a barrier in initiating patients on treatment may need to be revisited, as the closer we get to the second "90" goal of having 90% people diagnosed with HIV on treatment, the higher the importance of assuring that those patients who are on treatment are also appropriately monitored, such that the last "90" goal of having 90% people on treatment with viral suppression can be achieved.

Limitation {#Sec22}
==========

This review has some limitations that should be taken into account when interpreting the findings. Here, we identified only two studies that aimed to assess the monitoring and management of HIV patients. This paucity of data results in challenges regarding data interpretation and meant that we were unable to analyze and discuss differences in coverage of treatment monitoring services as well as quality of the services. Lack of information and data from unpublished government and program reports and studies published in non-English language may contribute to limited data availability. Moreover, limited data from studies conducted in SSA countries has made it difficult to generalize the findings outside the sub-Saharan African context.

Conclusions {#Sec23}
===========

The findings of this review suggest that there are potential major gaps in coverage and quality of treatment monitoring services for HIV patients on ART. Further studies particularly from non-SSA countries with longer-term of follow up are in need to assess the feasibility of treatment monitoring in the context of decentralization HIV treatment and care in LMICs. Significant investment in POC testing and, improving quality of and training for nursing staff to effectively manage patients on ART is required to improve quality of HIV treatment and care services. The development of a set of target program indicators for treatment monitoring is necessary to reinforce the importance of treatment monitoring in the HIV continuum of care toward achievement of the 90-90-90 goal by the year 2020.

Additional file {#Sec24}
===============

**Additional file 1: Annex S1.** Search strategy: Decentralization of HIV treatment and care in low and middle income countries.
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